1
|
Jansen G, Latka E, Deicke M, Fischer D, Gretenkort P, Hoyer A, Keller Y, Kobiella A, Ristau P, Seewald S, Strickmann B, Thies KC, Johanning K, Tiesmeier J. [Prehospital postcardiac-arrest-sedation and -care in the Federal Republic of Germany-a web-based survey of emergency physicians]. Med Klin Intensivmed Notfmed 2023:10.1007/s00063-023-01056-1. [PMID: 37682284 DOI: 10.1007/s00063-023-01056-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 07/12/2023] [Accepted: 07/24/2023] [Indexed: 09/09/2023]
Abstract
BACKGROUND This study evaluates the implementation of postcardiac-arrest-sedation (PCAS) and -care (PRC) by prehospital emergency physicians in Germany. MATERIALS AND METHODS Analysis of a web-based survey from October to November 2022. Questions were asked about implementation, medications used, complications, motivation for implementing or not implementing PCAS, and measures and target parameters of PRC. RESULTS A total of 500 emergency physicians participated in the survey. In all, 73.4% stated that they regularly performed PCAS (hypnotics: 84.7%; analgesics: 71.1%; relaxants: 29.7%). Indications were pressing against the respirator (88.3%), analgesia (74.1%), synchronization to respirator (59.5%), and change of airway device (52.6%). Reasons for not performing PCAS (26.6%) included unconscious patients (73.7%); concern about hypotension (31.6%), re-arrest (26.3%), and worsening neurological assessment (22.5%). Complications of PCAS were observed by 19.3% of participants (acute hypotension [74.6%]); (re-arrest [32.4%]). In addition to baseline monitoring, PRC included 12-lead-electrocardiogram (96.6%); capnography (91.6%); catecholamine therapy (77.6%); focused echocardiography (20.6%), lung ultrasound (12.0%) and abdominal ultrasound (5.6%); induction of hypothermia (13.6%) and blood gas analysis (7.4%). An etCO2 of 35-45 mm Hg was targeted by 40.6%, while 9.0% of participants targeted an SpO2 of 94-98% and 19.2% of participants targeted a systolic blood pressure of ≥ 100 mm Hg. CONCLUSIONS Prehospital PRC in Germany is heterogeneous and deviations from its target parameters are frequent. PCAS is frequent and associated with relevant complications. The development of preclinical care algorithms for PCAS and PRC within preclinical care seems urgently needed.
Collapse
Affiliation(s)
- G Jansen
- Universitätsklinikum für Anästhesiologie, Intensiv- und Notfallmedizin der Ruhr-Universität Bochum, Johannes Wesling Klinikum Minden, Minden, Deutschland.
- Universität Bielefeld, Medizinische Fakultät OWL, Universitätsstr. 25, 33615, Bielefeld, Deutschland.
- Fachbereich Medizin und Rettungswesen, Studieninstitut Westfalen-Lippe, Bielefeld, Deutschland.
| | - E Latka
- Fachbereich Medizin und Rettungswesen, Studieninstitut Westfalen-Lippe, Bielefeld, Deutschland
| | - M Deicke
- Ärztliche Leitung Rettungsdienst Landkreis Osnabrück, Osnabrück, Deutschland
| | - D Fischer
- Ärztliche Leitung Rettungsdienst Kreis Lippe, Detmold, Deutschland
| | - P Gretenkort
- Simulations- und Notfallakademie am Helios Klinikum Krefeld, Helios Klinikum Krefeld, Krefeld, Deutschland
| | - A Hoyer
- Biostatistik und Medizinische Biometrie, Medizinische Fakultät OWL, Universität Bielefeld, Bielefeld, Deutschland
| | - Y Keller
- Integrierte Regionalleitstelle Dresden, Geschäftsbereich Ordnung und Sicherheit, Brand- und Katastrophenschutzamt, Landeshauptstadt Dresden, Dresden, Deutschland
| | - A Kobiella
- Ärztliche Leitung Rettungsdienst Kreis Gütersloh, Gütersloh, Deutschland
| | - P Ristau
- Institut für Rettungs- und Notfallmedizin (IRuN), Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
| | - S Seewald
- Institut für Rettungs- und Notfallmedizin (IRuN), Universitätsklinikum Schleswig-Holstein, Kiel, Deutschland
- Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel, Deutschland
| | - B Strickmann
- Ärztliche Leitung Rettungsdienst Kreis Gütersloh, Gütersloh, Deutschland
| | - K C Thies
- Universitätsklinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Universitätsklinikum OWL der Universität Bielefeld, Evangelisches Klinikum Bielefeld, Bielefeld, Deutschland
| | - K Johanning
- Klinik für Anästhesiologie, operative Intensivmedizin, Notfallmedizin und Schmerztherapie, Universitätsklinikum OWL der Universität Bielefeld - Campus Klinikum Bielefeld, Bielefeld, Deutschland
| | - J Tiesmeier
- Institut für Anästhesiologie, Intensiv- und Notfallmedizin, MKK - Krankenhaus Lübbecke, Campus OWL der Ruhr-Universität Bochum, Lübbecke, Deutschland
| |
Collapse
|
2
|
Hsiao JM, Penalva YCM, Wu HYL, Xiao B, Jansen G, Dejgaard K, Young JC, Munter LM. Putative Protein Interactome of the Rhomboid Protease RHBDL4. Biochemistry 2023; 62:1209-1218. [PMID: 36857408 DOI: 10.1021/acs.biochem.2c00680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
The physiological functions of the rhomboid-related protein 4 (RHBDL4) are emerging, but their molecular details remain unclear. Because increased expression of RHBDL4 has been clinically linked to poorer outcomes in cancer patients, this association urgently demands a better understanding of RHBDL4. To elucidate the molecular interactions and pathways that RHBDL4 may be involved in, we conducted proximity-dependent biotin identification (BioID) assays. Our analyses corroborated several of the expected protein interactors such as the transitional endoplasmic reticulum (ER) ATPase VCP/p97 (TERA), but they also described novel putative interactors including IRS4, PGAM5, and GORS2. Using proximity-ligation assays, we validated VCP/p97, COPB, and VRK2 as proteins that are in proximity to RHBDL4. Overall, our results support the emerging functions of RHBDL4 in ER quality control and also point toward putative RHBDL4 functions in protein membrane insertion and membrane organization and trafficking.
Collapse
Affiliation(s)
| | - Ylauna Christine Mégane Penalva
- Department of Pharmacology & Therapeutics, McGill University, Montreal H3G 0B1, Québec, Canada
- Integrated Program in Neuroscience, McGill University, Montreal H3A 2B4, Québec, Canada
- Cell Information Systems Group, Bellini Life Sciences Complex, McGill University, Montreal H3G 0B1, Québec, Canada
| | - Helen Yee-Li Wu
- Department of Pharmacology & Therapeutics, McGill University, Montreal H3G 0B1, Québec, Canada
- Cell Information Systems Group, Bellini Life Sciences Complex, McGill University, Montreal H3G 0B1, Québec, Canada
| | - Bin Xiao
- Department of Pharmacology & Therapeutics, McGill University, Montreal H3G 0B1, Québec, Canada
- Cell Information Systems Group, Bellini Life Sciences Complex, McGill University, Montreal H3G 0B1, Québec, Canada
| | - Gregor Jansen
- Department of Biochemistry, McGill University, Montreal H3G 0B1, Québec, Canada
| | - Kurt Dejgaard
- Department of Biochemistry, McGill University, Montreal H3G 0B1, Québec, Canada
| | - Jason C Young
- Department of Biochemistry, McGill University, Montreal H3G 0B1, Québec, Canada
| | - Lisa Marie Munter
- Department of Pharmacology & Therapeutics, McGill University, Montreal H3G 0B1, Québec, Canada
- Cell Information Systems Group, Bellini Life Sciences Complex, McGill University, Montreal H3G 0B1, Québec, Canada
| |
Collapse
|
3
|
Nguyen TB, Zakhari N, Velasco Sandoval S, Guarnizo-Capera A, Alexios Gulak M, Woulfe J, Jansen G, Thornhill R, Majtenyi N, Cron GO. Diagnostic Accuracy of Arterial Spin-Labeling, Dynamic Contrast-Enhanced, and DSC Perfusion Imaging in the Diagnosis of Recurrent High-Grade Gliomas: A Prospective Study. AJNR Am J Neuroradiol 2023; 44:134-142. [PMID: 36702501 PMCID: PMC9891339 DOI: 10.3174/ajnr.a7771] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 12/30/2022] [Indexed: 01/27/2023]
Abstract
BACKGROUND AND PURPOSE For patients with high-grade gliomas, the appearance of a new, enhancing lesion after surgery and chemoradiation represents a diagnostic dilemma. We hypothesized that MR perfusion without and with contrast can differentiate tumor recurrence from radiation necrosis. MATERIALS AND METHODS In this prospective study, we performed 3 MR perfusion methods: arterial spin-labeling, DSC, and dynamic contrast enhancement. For each lesion, we measured CBF from arterial spin-labeling, uncorrected relative CBV, and leakage-corrected relative CBV from DSC imaging. The volume transfer constant and plasma volume were obtained from dynamic contrast-enhanced imaging without and with T1 mapping using modified Look-Locker inversion recovery (MOLLI). The diagnosis of tumor recurrence or radiation necrosis was determined by either histopathology for patients who underwent re-resection or radiologic follow-up for patients who did not have re-resection. RESULTS There were 26 patients with 32 lesions, 19 lesions with tumor recurrence and 13 lesions with radiation necrosis. Compared with radiation necrosis, lesions with tumor recurrence had higher CBF (P = .033), leakage-corrected relative CBV (P = .048), and plasma volume using MOLLI T1 mapping (P = .012). For differentiating tumor recurrence from radiation necrosis, the areas under the curve were 0.81 for CBF, 0.80 for plasma volume using MOLLI T1 mapping, and 0.71 for leakage-corrected relative CBV. A correlation was found between CBF and leakage-corrected relative CBV (r s = 0.54), volume transfer constant, and plasma volume (0.50 < r s< 0.77) but not with uncorrected relative CBV (r s = 0.20, P = .29). CONCLUSIONS In the differentiation of tumor recurrence from radiation necrosis in a newly enhancing lesion, the diagnostic value of arterial spin-labeling-derived CBF is similar to that of DSC and dynamic contrast-enhancement-derived blood volume.
Collapse
Affiliation(s)
- T B Nguyen
- From the Department of Radiology (T.B.N., N.Z., R.T.), Radiation Oncology and Medical Physics
- University of Ottawa (T.B.N., N.Z., J.W., G.J., R.T.), Ottawa, Ontario, Canada
- The Ottawa Hospital Research Institute (T.B.N., J.W., G.J., R.T.), Ottawa, Ontario, Canada
| | - N Zakhari
- From the Department of Radiology (T.B.N., N.Z., R.T.), Radiation Oncology and Medical Physics
- University of Ottawa (T.B.N., N.Z., J.W., G.J., R.T.), Ottawa, Ontario, Canada
| | - S Velasco Sandoval
- Division of Neuroradiology (S.V.S., A.G.-C.), Department of Radiology, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia
| | - A Guarnizo-Capera
- Division of Neuroradiology (S.V.S., A.G.-C.), Department of Radiology, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, D.C., Colombia
| | - M Alexios Gulak
- Department of Anesthesiology and Pain Medicine (M.A.G.), University of Toronto, Toronto, Ontario, Canada
| | - J Woulfe
- Department of Pathology and Laboratory Medicine (J.W., G.J.), The Ottawa Hospital, Ottawa, Ontario, Canada
- University of Ottawa (T.B.N., N.Z., J.W., G.J., R.T.), Ottawa, Ontario, Canada
- The Ottawa Hospital Research Institute (T.B.N., J.W., G.J., R.T.), Ottawa, Ontario, Canada
| | - G Jansen
- Department of Pathology and Laboratory Medicine (J.W., G.J.), The Ottawa Hospital, Ottawa, Ontario, Canada
- University of Ottawa (T.B.N., N.Z., J.W., G.J., R.T.), Ottawa, Ontario, Canada
- The Ottawa Hospital Research Institute (T.B.N., J.W., G.J., R.T.), Ottawa, Ontario, Canada
| | - R Thornhill
- From the Department of Radiology (T.B.N., N.Z., R.T.), Radiation Oncology and Medical Physics
- University of Ottawa (T.B.N., N.Z., J.W., G.J., R.T.), Ottawa, Ontario, Canada
- The Ottawa Hospital Research Institute (T.B.N., J.W., G.J., R.T.), Ottawa, Ontario, Canada
| | - N Majtenyi
- Department of Medical Physics (N.M.), Grand River Regional Cancer Centre, Kitchener, Ontario, Canada
| | - G O Cron
- Stanford University (G.O.C.), Stanford, California
| |
Collapse
|
4
|
Hebing R, Lin M, Struys E, Mahmoud S, Muller I, Heil S, Griffioen P, Lems W, Van den Bemt B, Nurmohamed M, Jansen G, De Jonge R. POS0411 COMPARISON OF MTX-POLYGLUTAMATE ACCUMULATION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND ERYTHROCYTES DURING 6 MONTHS MTX-THERAPY IN THE METHOTREXATE MONITORING (MeMo) TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundOptimal dosing of methotrexate (MTX) in rheumatoid arthritis (RA) remains challenging. To this end, monitoring of intracellular MTX polyglutamates (MTX-PGs) in red blood cells (RBCs) has been investigated as a potential marker of MTX (non-)response, with contradictory results. As enucleated, non-proliferative cells, mature RBCs lack regulated folate metabolism and are devoid of folylpolyglutamate synthetase (FPGS) activity catalyzing the conversion of MTX to MTX-PGs. Therefore, it has been argued that analysis of MTX-PG in immune-effector cells, represented by peripheral blood mononuclear cells (PBMCs), would be more relevant. However, no prospective study has been performed measuring MTX-PG levels in PBMCs nor in comparison with RBCs.ObjectivesTo investigate the pharmacokinetics of MTX-PG accumulation in RBCs and PBMCs in newly diagnosed RA patients in the early phase of MTX treatment.MethodsIn a clinical prospective cohort study (Methotrexate Monitoring (NTR7149)), RA patients were administered MTX op to 25 mg/week, as described before. (1) At 1, 2, 3 and 6 months after start of therapy, blood was collected and RBCs were isolated by centrifugation and PBMCs after Ficoll density gradient centrifugation. MTX-PG1-6 concentrations in these cells were analyzed using a UPLC-MS/MS method with including custom-made stable isotopes of MTX-PG1-6 as internal standards. (2) UPLC-MS/MS measurements for MTX-PG1-6 were performed with a Waters Acquity BEH C18 column coupled to an AB Sciex 6500+ with the ESI operating on the positive mode. MTX dosing and concomitant treatments were in conformity with clinical practice. (3)Results46 consecutive patients were included in this study; 76% female, mean age: 57.8 years, mean baseline DAS28-ESR: 3.5, as described before. (1) Mean dosage was 10.5 mg (SD: 1.5) at baseline, 16.3 mg (2.5) at month 1, 22.7 mg (4.5) at month 2, 19.5 mg (6.3) at month 3 and 19.1 mg (6.2) at month 6.MTX-PG accumulation in PBMCs and RBCs revealed a disparate profile in both MTX-PG distribution and absolute accumulation levels (Figure 1A/B). Remarkably, MTX-PG distribution in PBMCs was mainly composed of MTX-PG1 (58%), and to a lesser extent MTX-PG2 (27%) and MTX-PG3 (15%). Longer chain MTX-PG4-6 were also detectable in PBMCs, but at lower levels (mean: 4.0 – 6.7 fmol/10^6 cells) than MTX-PG1-3. Moreover, this MTX-PG distribution profile in PBMCs remained constant over a MTX therapy period of 6 months (Figure 1A). The RBC MTX-PG accumulation profile shows mainly MTX-PG1 and lower levels of MTX-PG2-6 at 1 month after the start of therapy. After 3 months of therapy, MTX-PG3 is the main PG-moiety with also MTX-PG4,5,6 being detected. This profile is largely similar after 6 months of therapy. With respect to total intracellular MTX-PG1-6 accumulation, PBMCs had significantly (p<0.001) 10-20-fold higher levels than RBCs at all analyzed time points (Figure 1A/B). Total MTX-PG1-6 levels in RBCs and PBMCs at all time points were weakly correlated (r=0.41, p<0.01) (Figure 1C).Figure 1.Individual MTX-PG concentrations in PBMCs (A) and RBCs (B) during the first 6 months of MTX administration (note the different scaling of the y-axes). At 6 months, 36 patients were still on MTX treatment. Panel (C): Spearman’s correlation plot of total MTX-PGs in RBCs versus PBMCs of all time points.The disparate MTX-PG accumulation and distribution profiles in PBMCs versus RBCs of RA patients may be associated with the shorter life span of PBMCs and the low FPGS activity in RBCs. (4)No significant relation between MTX-PGs and DAS28 was found (data not shown).ConclusionThis study shows that in newly diagnosed RA patients starting MTX therapy, MTX-PG concentrations in PBMCs are significantly 10-20-fold higher than in RBCs over a period of 6 months, with a disparate MTX-PG distribution profile in PBMCs (highest: MTX-PG1) than RBCs (highest: MTX-PG3).References[1]RCF Hebing, Arthr Rheum (2021)[2]E den Boer, Anal Bioanal Chem (2013)[3]J Smolen, Ann Rheum Dis (2020)[4]IB Muller, Ther Drug Monit (2019)AcknowledgementsAcknowledgements: We would like to thank all participating patients and Pfizer (grant 53233663 / WI230458), AmsterdamUMC (AI&II extension grant) and NVKC (Noyons grant 2018)Disclosure of InterestsRenske Hebing Grant/research support from: Pfizer (grant 53233663 / WI230458), NVKC (Netherlands Society for Clinical Chemistry, Noyons grant 2018) and AmsterdamUMC (extension grant), Marry Lin: None declared, Eduard Struys: None declared, Sohaila Mahmoud: None declared, Ittai Muller: None declared, Sandra Heil: None declared, Pieter Griffioen: None declared, WIllem Lems: None declared, Bart van den Bemt Speakers bureau: Pfizer, UCB, Sanofi-Aventis, Galapagos, Amgen and Eli Lilly, Michael Nurmohamed Grant/research support from: Pfizer grant 53233663 / WI230458, Gerrit Jansen: None declared, Robert De Jonge Grant/research support from: NVKC (Netherlands Society for Clinical Chemistry, Noyons grant)
Collapse
|
5
|
Hebing R, Lin M, Struys E, Mahmoud S, Muller I, Lems W, van den Bemt B, Jansen G, De Jonge R, Nurmohamed M. AB0061 PHARMACOKINETICS OF METHOTREXATE POLYGLUTAMATES IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF RA PATIENTS IS SIMILAR AFTER SUBCUTANEOUS OR ORAL ADMINISTRATION IN THE METHOTREXATE MONITORING (MeMo) TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPharmacokinetics of methotrexate (MTX) after oral and subcutaneous administration to RA patients differs: MTX levels in plasma and MTX-polyglutamate (MTX-PG) accumulation in erythrocytes are higher during equidosed subcutaneous compared to oral MTX treatment. (1,2) No data are available whether administration route of MTX differentially impacts the intracellular concentrations of MTX-PGs in peripheral blood mononuclear cells (PBMCs) during MTX therapy.ObjectivesTo investigate the pharmacokinetics of MTX-PGs in PBMCs of newly diagnosed RA patients receiving oral or subcutaneous MTX in the early phase (1, 2, 3 and 6 months) of MTX treatment.MethodsIn a clinical prospective cohort study (MeMo study (NTR7149)), RA patients wereadministered oral (n=24) or subcutaneous (n=22) MTX up to 25 mg MTX/week, as described before. (1) At 1, 2, 3 and 6 months after the start of therapy, PBMCs were isolated via Ficoll density gradient centrifugation. Individual MTX-PG forms (MTX-PG1-6) in PBMCs were analyzed by a UPLC-MS/MS method including custom-made stable isotopes of MTX-PG1-6 as internal standards (3). UPLC-MS/MS measurements of the PBMCs were performed with a Waters Acquity BEH C18 column coupled to an AB Sciex 6500+ with the ESI operating on the positive mode. Dosing, concomitant treatments and DAS28-ESR assessments were in conformity with clinical practice. (4)Results46 consecutive patients were included in this study; 76% female, mean age: 57.8 years, BMI: 25.8, smokers: 20%, mean baseline DAS28-ESR: 3.5, as described before. (1) MTX dose at baseline was 10.5 mg (SD: 1.5) for both groups, 15.4 mg (4.4) and 16.8 mg (1.8) at 1 month, 22.8 mg (3.9) and 22.4 mg (5.2) at 2 months, 20.1 mg (6.3) and 20.8 mg (5.6) at 3 months, and 19.7 mg (6.1) and 18.5 mg (6.7) at 6 months for oral and subcutaneous use, respectively. MTX-PG analyses in PBMCs for individual and total MTX-PGs revealed no significant differences between oral and subcutaneous administration groups at 1, 2, 3, and 6 months (Figure 1). Linear regression of LN transformed MTX-PG levels in PBMCs and administration route, corrected for age, baseline DAS28, smoking, BMI, eGFR and MTX dose, showed a trend towards higher MTX-PG levels in PBMCs after subcutaneous MTX administration compared to oral administration (data not shown). MTX-PG distribution in PBMCs was mainly composed of MTX-PG1 (58%), and to a lesser extent MTX-PG2 (27%) and MTX-PG3 (15%). Longer chain MTX-PGs beyond MTX-PG4 were detectable in PBMCs, but at levels lower than MTX-PG1-3 (mean: 4.0 – 6.7 fmol/106 cells). Total MTX-PG accumulation in PBMCs was approximately 10-20 fold higher than in erythrocytes. PBMC accumulation was rather stable, whereas RBC MTX-PG accumulation increased between 1 to 3 months to reach a plateau (Figure 1).Figure 1.Loess regression of MTX-PG concentrations in PBMCs (MTX-PG1-3) and RBCs (MTX-PG1-6) of RA patients during the first 6 months of oral or subcutaneous MTX administration. At 6 months, 18 patients using oral and 18 patients using subcutaneous MTX were still continuing MTX treatment. Means (lines) and SE (grey areas) are depicted.ConclusionThis study demonstrated that MTX-PG accumulation in PBMCs early on in the MTX treatment of RA patients was not significantly different between oral or subcutaneous MTX administration routes.References[1]RCF Hebing et al, Arthritis Rheum (2021); 60:339-348[2]M Hoekstra et al, J Rheumatol (2004); 31:645-8[3]E Den Boer et al, Anal Bioanal Chem (2013); 405: 1673-1681[4]J Smolen et al, Ann Rheum Dis (2020); 79:685-699AcknowledgementsWe would like to thank all participating patients and Pfizer (grant 53233663 / WI230458), NVKC (Noyons grant) and AmsterdamUMC (AI&II extension grant).Disclosure of InterestsRenske Hebing Grant/research support from: Pfizer, grant number 53233663 / WI230458, Amsterdam UMC (AI&II extension grant), NVKC (Netherlands Society for Clinical Chemistry, Noyons grant), Marry Lin: None declared, Eduard Struys: None declared, Sohaila Mahmoud: None declared, Ittai Muller: None declared, WIllem Lems: None declared, Bart van den Bemt Speakers bureau: Pfizer, UCB, Sanofi-Aventis, Galapagos, Amgen and Eli Lilly, Gerrit Jansen: None declared, Robert De Jonge Grant/research support from: NVKC (Netherlands Society for Clinical Chemistry, Noyons grant), Michael Nurmohamed Grant/research support from: Pfizer grant
Collapse
|
6
|
Jansen G, Kappelhoff N, Borgstedt R, Rehberg S, Seewald S, Scholz SS. [In-hospital emergency care in the Federal Republic of Germany. A site survey of hospitals in the German Resuscitation Registry]. Anaesthesist 2021; 71:502-509. [PMID: 34889966 DOI: 10.1007/s00101-021-01075-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2021] [Revised: 11/04/2021] [Accepted: 11/14/2021] [Indexed: 10/19/2022]
Abstract
BACKGROUND In contrast to prehospital care there is a lack of specifications for the organization and equipment of medical emergency teams for in-hospital emergency care. OBJECTIVE Evaluation of the organization, team composition, training, equipment and tasks of medical emergency teams in the Federal Republic of Germany. MATERIAL AND METHODS Evaluation of a web-based survey of all hospitals participating in the German Resuscitation Register between February and March2020. The participants were asked about team composition; emergency equipment; type, content and scope of special training or further training as well as other additional tasks in the everyday clinical routine when participating in the medical emergency team. Hospitals with ≤ or >600 beds were compared. RESULTS A total of 21 (>600 beds: 10, 48%; ≤600 beds: 11, 52%) hospitals participated in the survey. Team composition requirements were present at 76% (n = 16; ≤600 beds: 8, 72% vs. >600 beds: 8, 80%), training requirements for medical emergency teams at 38% (n = 16; ≤600 beds: 4, 36% vs. >600 beds: 4, 40%) of hospitals, with a focus on cardiac life support (n = 6, 28%; ≤600 beds: 3, 27% vs. >600 beds: 3, 30%) and airway management (n = 4, 19%; ≤600 beds: 3, 27% vs. >600 beds: 1, 10%). A 12-lead electrocardiogram (n = 7, 33%; ≤600 beds: 1, 9% vs. >600 beds: 6, 60%; p = 0.02), video laryngoscope (n = 7, 33%; ≤600 beds: 2, 18% vs. >600 beds: 5, 50%), ventilator without (n = 7, 33%; ≤600 beds: 2, 18% vs. >600 beds: 5, 50%) or with the possibility of non-invasive ventilation was part of the standard equipment in n = 4, 19% (≤600 beds: 1, 9% vs. >600 beds: 3, 30%). A total of 85% (n = 18; ≤600 beds: 10, 100% vs. >600 beds 8, 72%), had additional tasks in the daily clinical routine. While clinics with >600 beds staffed medical emergency teams 100% of the time from the intensive care units, in clinics ≤600 beds medical emergency teams were deployed significantly more often in the emergency department (n = 5, 45%) and in the normal wards (n = 5, 45%, p = 0.03). CONCLUSION Training and equipment of medical emergency teams in the Federal Republic of Germany is heterogeneous. They should at least meet the standards commonly used in prehospital emergency medicine and include the availability of a portable 12-lead electrocardiogram, a ventilator with the possibility of noninvasive ventilation and a video laryngoscope. Regardless of the size of the hospital, continuous availability of all members of the medical emergency teams should be ensured.
Collapse
Affiliation(s)
- G Jansen
- Universitätsklinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Evangelisches Klinikum Bethel, Universitätsklinikum Bielefeld, Campus Bielefeld - Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland.
| | - N Kappelhoff
- Universitätsklinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Evangelisches Klinikum Bethel, Universitätsklinikum Bielefeld, Campus Bielefeld - Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland
| | - R Borgstedt
- Universitätsklinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Evangelisches Klinikum Bethel, Universitätsklinikum Bielefeld, Campus Bielefeld - Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland
| | - S Rehberg
- Universitätsklinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Evangelisches Klinikum Bethel, Universitätsklinikum Bielefeld, Campus Bielefeld - Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland
| | - S Seewald
- Deutsches Reanimationsregister, Kiel, Deutschland
| | - S S Scholz
- Universitätsklinik für Anästhesiologie, Intensiv‑, Notfallmedizin, Transfusionsmedizin und Schmerztherapie, Evangelisches Klinikum Bethel, Universitätsklinikum Bielefeld, Campus Bielefeld - Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland
| |
Collapse
|
7
|
Hebing R, Muller I, Lin M, Mahmoud S, Heil S, Lems W, Nurmohamed M, De Jonge R, Jansen G. AB0251 INCREASED ACCUMULATION OF ERYTHROCYTE METHOTREXATE POLYGLUTAMATES DURING EARLY PHASE SUBCUTANEOUS VERSUS ORAL METHOTREXATE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Optimal dosing of methotrexate (MTX) for individual rheumatoid arthritis (RA) patients to achieve adequate disease control is an ongoing challenge. Assessment of erythrocyte MTX-polyglutamates (PGs) levels has been employed as a tool to monitor clinical response of RA patients in the first 3-12 months of treatment and MTX-PG2-4 and total MTX-PGs were associated with a lower DAS28 over 9 months.1 However, data from earlier time points, MTX-PG6 and per route of administration are unavailable.Objectives:To investigate the pharmacokinetics and -dynamics of erythrocyte MTX-PG accumulation in RA patients receiving oral or subcutaneous MTX in the early phase (1, 2, and 3 months) of MTX treatment initiation.Methods:In a clinical prospective cohort study (MeMo study (NTR7149)), newly diagnosed RA patients were administered oral (n=24) or subcutaneous (n=22) MTX, mostly according to the COBRA-light schedule (start 10 mg MTX, increased to 25 mg MTX in 8 weeks). At 1, 2, and 3 months after start of therapy, blood was collected and individual MTX-PGs (MTX-PG1 – MTX-PG6) were analyzed in erythrocytes at a minimal detection limit of 1 nmol/L, using a validated UHPLC-MS/MS method with labeled internal standards.1 Dosing, concomitant treatments and DAS28-ESR assessments were in conformity with clinical practice. Adverse events were recorded.Results:46 consecutive patients were included in this study; 76% female, mean age: 57.8 years, BMI: 25.8, 20% smokers, mean baseline DAS28-ESR: 3.5. Notwithstanding marked interpatient variability, patients starting subcutaneous MTX had accumulated significantly higher (approximately 2-fold) long chain MTX-PGs (MTX-PG4-6) when compared to patients in the oral MTX group at 1 and 2 months (Figure 1A, Table 1). Similarly, MTX-PG1-6 and MTX-PG3 accumulation were higher in subcutaneous MTX-users at month 1 (p=0.022 and p=0.011) compared to the oral group (median 68.6 nmol/L (IQR:40.5) vs 51.9 (55.6) and 17.4 (11.1) vs 11.2 (15.6), respectively (Figure 1B, Table 1).Table 1.Linear regression of MTX-PG levels and administration route, corrected for age, baseline DAS28, smoking, BMI, eGFR and MTX dose.monthß (P-value)1ß (P-value)2ß (P-value)3MTX-PG1-61.65 (0.022)1.51 (0.073)1.30 (0.233)MTX-PG1,21.13 (0.599)1.19 (0.470)1.12 (0.623)MTX-PG31.75 (0.011)1.51 (0.071)1.19 (0.439)MTX-PG4-61.97 (0.036)2.04 (0.033)1.55 (0.136)Mean MTX dose at baseline was 10.5mg (SD 1.5) for both groups, 15.4 (4.4) and 16.8 (1.8) at 1 month and 22.8 (3.9) and 22.4 (5.2) at 2 months for oral and subcutaneous use respectively.DAS28 decreased with 1.6 in the oral group and 1.1 in the subcutaneous group (p=0.382). With and without corrections for age, baseline DAS28, eGFR, MTX dose (1 month before sampling), smoking and BMI, no significant relation between MTX-PG concentrations and DAS28 was observed during the first 3 months of treatment.43 patients reported any side effect, mostly headache and dizziness, which was similar in both groups and uncorrelated with MTX-PG levels.No association was found between MTX-PG1 levels and number of days between timing of blood withdrawal and last administration.Figure 1.Erythrocyte long chain MTX-PG(A) and total MTX-PG(B) accumulation in RA patients of the first 3 months of oral(C) or subcutaneous(D) MTX administration. At 3 months, 18 patients using oral and 18 patients using subcutaneous MTX were still continuing MTX treatment. Medians and IQR are depicted.Conclusion:This study shows the feasibility of measuring erythrocyte MTX-PGs early on in the treatment of RA patients with MTX and demonstrated significantly higher accumulation of MTX-PGs following subcutaneous versus oral MTX administration. Early phase erythrocyte MTX-PG analyses may hold potential for positioning in optimizing individual patient MTX dose scheduling.References:[1]de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 2015(74):408-14.Acknowledgements:We would like to thank all participating patients and Pfizer (grant 53233663 / WI230458).Disclosure of Interests:Renske Hebing Grant/research support from: Pfizer, Ittai Muller: None declared, Marry Lin: None declared, Sohaila Mahmoud: None declared, Sandra Heil: None declared, WIllem Lems: None declared, Michael Nurmohamed: None declared, Robert De Jonge: None declared, Gerrit Jansen: None declared
Collapse
|
8
|
Muller I, Verhoeven M, Gosselt H, Lin M, De Jong T, Mantel E, Chatzidionysiou K, Jansen G, Padyukov L, Welsing P, Lafeber F, De Jonge R, Van der Laken CJ. OP0021 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN EARLY RHEUMATOID ARTHRITIS PATIENTS RESPONDING TO TOCILIZUMAB. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Tocilizumab (TCZ) is a monoclonal antibody that binds to the interleukin 6 receptor (IL-6R), inhibiting IL-6R signal transduction to downstream inflammatory mediators. TCZ has shown to be effective as monotherapy in early rheumatoid arthritis (RA) patients (1). However, approximately one third of patients inadequately respond to therapy and the biological mechanisms underlying lack of efficacy for TCZ remain elusive (1). Here we report gene expression differences, in both whole blood and peripheral blood mononuclear cells (PBMC) RNA samples between early RA patients, categorized by clinical TCZ response (reaching DAS28 < 3.2 at 6 months). These findings could lead to identification of predictive biomarkers for TCZ response and improve RA treatment strategies.Objectives:To identify potential baseline gene expression markers for TCZ response in early RA patients using an RNA-sequencing approach.Methods:Two cohorts of RA patients were included and blood was collected at baseline, before initiating TCZ treatment (8 mg/kg every 4 weeks, intravenously). DAS28-ESR scores were calculated at baseline and clinical response to TCZ was defined as DAS28 < 3.2 at 6 months of treatment. In the first cohort (n=21 patients, previously treated with DMARDs), RNA-sequencing (RNA-seq) was performed on baseline whole blood PAXgene RNA (Illumina TruSeq mRNA Stranded) and differential gene expression (DGE) profiles were measured between responders (n=14) and non-responders (n=7). For external replication, in a second cohort (n=95 therapy-naïve patients receiving TCZ monotherapy), RNA-seq was conducted on baseline PBMC RNA (SMARTer Stranded Total RNA-Seq Kit, Takara Bio) from the 2-year, multicenter, double-blind, placebo-controlled, randomized U-Act-Early trial (ClinicalTrials.gov identifier: NCT01034137) and DGE was analyzed between 84 responders and 11 non-responders.Results:Whole blood DGE analysis showed two significantly higher expressed genes in TCZ non-responders (False Discovery Rate, FDR < 0.05): urotensin 2 (UTS2) and caveolin-1 (CAV1). Subsequent analysis of U-Act-Early PBMC DGE showed nine differentially expressed genes (FDR < 0.05) of which expression in clinical TCZ non-responders was significantly higher for eight genes (MTCOP12, ZNF774, UTS2, SLC4A1, FECH, IFIT1B, AHSP, and SPTB) and significantly lower for one gene (TND2P28M). Both analyses were corrected for baseline DAS28-ESR, age and gender. Expression of UTS2, with a proposed function in regulatory T-cells (2), was significantly higher in TCZ non-responders in both cohorts. Furthermore, gene ontology enrichment analysis revealed no distinct gene ontology or IL-6 related pathway(s) that were significantly different between TCZ-responders and non-responders.Conclusion:Several genes are differentially expressed at baseline between responders and non-responders to TCZ therapy at 6 months. Most notably, UTS2 expression is significantly higher in TCZ non-responders in both whole blood as well as PBMC cohorts. UTS2 could be a promising target for further analyses as a potential predictive biomarker for TCZ response in RA patients in combination with clinical parameters (3).References:[1]Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343-55.[2]Bhairavabhotla R, Kim YC, Glass DD, et al. Transcriptome profiling of human FoxP3+ regulatory T cells. Human Immunology. 2016;77(2):201-13.[3]Gosselt HR, Verhoeven MMA, Bulatovic-Calasan M, et al. Complex machine-learning algorithms and multivariable logistic regression on par in the prediction of insufficient clinical response to methotrexate in rheumatoid arthritis. Journal of Personalized Medicine. 2021;11(1).Disclosure of Interests:None declared
Collapse
|
9
|
Driehuis E, Oosterom N, Heil SG, Muller IB, Lin M, Kolders S, Jansen G, de Jonge R, Pieters R, Clevers H, van den Heuvel-Eibrink MM. Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia. PLoS One 2020; 15:e0231588. [PMID: 32421698 PMCID: PMC7233536 DOI: 10.1371/journal.pone.0231588] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 03/27/2020] [Indexed: 12/22/2022] Open
Abstract
We have recently established a protocol to grow wildtype human oral mucosa organoids. These three-dimensional structures can be maintained in culture long-term, do not require immortalization, and recapitulate the multilayered composition of the epithelial lining of the oral mucosa. Here, we validate the use of this model to study the effect of Leucovorin (LV) on Methotrexate (MTX)-induced toxicity. MTX is a chemotherapeutic agent used in the treatment of pediatric acute lymphoblastic leukemia. Although effective, the use of MTX often results in severe side-effects, including oral mucositis, which is characterized by epithelial cell death. Here, we show that organoids are sensitive to MTX, and that the addition of LV reduces MTX toxicity, in both a concentration- and timing-dependent manner. Additionally, we show that a 24 hour ‘pretreatment’ with LV reduces MTX-induced cell death, suggesting that such a pretreatment could decrease mucositis in patients. Taken together, we provide the first in vitro model to study the effect of MTX on wildtype oral mucosa cells. Our findings underscore the relevance of the clinically applied LV regimen and highlight the potential of this model to further optimize modifications in dosing and timing of Leucovorin on oral mucosa cells.
Collapse
Affiliation(s)
- E. Driehuis
- Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, The Netherlands
| | - N. Oosterom
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - S. G. Heil
- Department of Clinical Chemistry, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - I. B. Muller
- Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands
| | - M. Lin
- Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands
| | - S. Kolders
- Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, The Netherlands
| | - G. Jansen
- Amsterdam Rheumatology and Immunology Center, Department of Rheumatology, Amsterdam UMC, Amsterdam, The Netherlands
| | - R. de Jonge
- Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, The Netherlands
| | - R. Pieters
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - H. Clevers
- Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, The Netherlands
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | | |
Collapse
|
10
|
Maurel M, Obacz J, Avril T, Ding YP, Papadodima O, Treton X, Daniel F, Pilalis E, Hörberg J, Hou W, Beauchamp MC, Tourneur-Marsille J, Cazals-Hatem D, Sommerova L, Samali A, Tavernier J, Hrstka R, Dupont A, Fessart D, Delom F, Fernandez-Zapico ME, Jansen G, Eriksson LA, Thomas DY, Jerome-Majewska L, Hupp T, Chatziioannou A, Chevet E, Ogier-Denis E. Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation. EMBO Mol Med 2020; 11:emmm.201810120. [PMID: 31040128 PMCID: PMC6554669 DOI: 10.15252/emmm.201810120] [Citation(s) in RCA: 46] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Anterior gradient 2 (AGR2) is a dimeric protein disulfide isomerase family member involved in the regulation of protein quality control in the endoplasmic reticulum (ER). Mouse AGR2 deletion increases intestinal inflammation and promotes the development of inflammatory bowel disease (IBD). Although these biological effects are well established, the underlying molecular mechanisms of AGR2 function toward inflammation remain poorly defined. Here, using a protein-protein interaction screen to identify cellular regulators of AGR2 dimerization, we unveiled specific enhancers, including TMED2, and inhibitors of AGR2 dimerization, that control AGR2 functions. We demonstrate that modulation of AGR2 dimer formation, whether enhancing or inhibiting the process, yields pro-inflammatory phenotypes, through either autophagy-dependent processes or secretion of AGR2, respectively. We also demonstrate that in IBD and specifically in Crohn's disease, the levels of AGR2 dimerization modulators are selectively deregulated, and this correlates with severity of disease. Our study demonstrates that AGR2 dimers act as sensors of ER homeostasis which are disrupted upon ER stress and promote the secretion of AGR2 monomers. The latter might represent systemic alarm signals for pro-inflammatory responses.
Collapse
Affiliation(s)
- Marion Maurel
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", University of Rennes, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France.,VIB Department of Medical Protein Research, UGent, Gent, Belgium.,Apoptosis Research Centre, School of Natural Sciences, NUI Galway, Galway, Ireland
| | - Joanna Obacz
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", University of Rennes, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Tony Avril
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", University of Rennes, Rennes, France.,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Yong-Ping Ding
- INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France.,Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.,APHP Beaujon Hospital Clichy la Garenne, Paris, France
| | - Olga Papadodima
- Institute of Biology, Medicinal Chemistry & Biotechnology, NHRF, Athens, Greece
| | - Xavier Treton
- INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France.,Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.,APHP Beaujon Hospital Clichy la Garenne, Paris, France
| | - Fanny Daniel
- INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France.,Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.,APHP Beaujon Hospital Clichy la Garenne, Paris, France
| | - Eleftherios Pilalis
- Institute of Biology, Medicinal Chemistry & Biotechnology, NHRF, Athens, Greece.,International Centre for Cancer Vaccine Science, Gdansk, Poland
| | - Johanna Hörberg
- Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden
| | - Wenyang Hou
- Departments of Anatomy and Cell Biology, Human Genetics, and Pediatrics, McGill University, Montreal, QC, Canada
| | - Marie-Claude Beauchamp
- Departments of Anatomy and Cell Biology, Human Genetics, and Pediatrics, McGill University, Montreal, QC, Canada
| | - Julien Tourneur-Marsille
- INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France.,Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.,APHP Beaujon Hospital Clichy la Garenne, Paris, France
| | - Dominique Cazals-Hatem
- INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France.,Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.,APHP Beaujon Hospital Clichy la Garenne, Paris, France
| | - Lucia Sommerova
- Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic
| | - Afshin Samali
- Apoptosis Research Centre, School of Natural Sciences, NUI Galway, Galway, Ireland
| | - Jan Tavernier
- VIB Department of Medical Protein Research, UGent, Gent, Belgium
| | - Roman Hrstka
- Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic
| | - Aurélien Dupont
- Microscopy Rennes Imaging Centre, and Biosit, UMS3480 CNRS, University of Rennes 1, Rennes Cédex, France
| | | | | | - Martin E Fernandez-Zapico
- Division of Oncology Research, Department of Oncology, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN, USA
| | - Gregor Jansen
- Biochemistry Department, McGill University Life Sciences Complex, Montréal, QC, Canada
| | - Leif A Eriksson
- Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden
| | - David Y Thomas
- Biochemistry Department, McGill University Life Sciences Complex, Montréal, QC, Canada
| | - Loydie Jerome-Majewska
- Departments of Anatomy and Cell Biology, Human Genetics, and Pediatrics, McGill University, Montreal, QC, Canada
| | - Ted Hupp
- International Centre for Cancer Vaccine Science, Gdansk, Poland.,Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic.,Edinburgh Cancer Research Centre at the Institute of Genetics and Molecular Medicine, Edinburgh University, Edimburgh, UK
| | - Aristotelis Chatziioannou
- Institute of Biology, Medicinal Chemistry & Biotechnology, NHRF, Athens, Greece .,e-NIOS PC, Kallithea-Athens, Greece
| | - Eric Chevet
- INSERM U1242, "Chemistry, Oncogenesis Stress Signaling", University of Rennes, Rennes, France .,Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France
| | - Eric Ogier-Denis
- INSERM, UMR1149, Team «Gut Inflammation», Research Centre of Inflammation, Paris, France .,Université Paris-Diderot Sorbonne Paris-Cité, Paris, France.,APHP Beaujon Hospital Clichy la Garenne, Paris, France
| |
Collapse
|
11
|
Jansen G. Book Review: Pain Care Essentials and Innovations. J Rehabil Med 2020. [DOI: 10.2340/16501977-2745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Hanrahan JW, Sato Y, Carlile GW, Jansen G, Young JC, Thomas DY. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets. Expert Opin Ther Targets 2019; 23:711-724. [PMID: 31169041 DOI: 10.1080/14728222.2019.1628948] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Introduction: Cystic fibrosis (CF) is the most frequent lethal orphan disease and is caused by mutations in the CFTR gene. The most frequent mutation F508del-CFTR affects multiple organs; infections and subsequent infections and complications in the lung lead to death. Areas covered: This review focuses on new targets and mechanisms that are attracting interest for the development of CF therapies. The F508del-CFTR protein is retained in the endoplasmic reticulum (ER) but has some function if it can traffic to the plasma membrane. Cell-based assays have been used to screen chemical libraries for small molecule correctors that restore its trafficking. Pharmacological chaperones are correctors that bind directly to the F508del-CFTR mutant and promote its folding and trafficking. Other correctors fall into a heterogeneous class of proteostasis modulators that act indirectly by altering cellular homeostasis. Expert opinion: Pharmacological chaperones have so far been the most successful correctors of F508del-CFTR trafficking, but their level of correction means that more than one corrector is required. Proteostasis modulators have low levels of correction but hold promise because some can correct several different CFTR mutations. Identification of their cellular targets and the potential for development may lead to new therapies for CF.
Collapse
Affiliation(s)
- John W Hanrahan
- a Department of Physiology , McGill University , Montréal , QC , Canada.,c Research Institute of the McGill University Health Centre , McGill University , Montréal , QC , Canada
| | - Yukiko Sato
- a Department of Physiology , McGill University , Montréal , QC , Canada.,b Cystic Fibrosis Translational Research centre , McGill University , Montréal , QC , Canada
| | - Graeme W Carlile
- b Cystic Fibrosis Translational Research centre , McGill University , Montréal , QC , Canada.,d Department of Biochemistry , McGill University , Montréal , QC , Canada
| | - Gregor Jansen
- d Department of Biochemistry , McGill University , Montréal , QC , Canada
| | - Jason C Young
- b Cystic Fibrosis Translational Research centre , McGill University , Montréal , QC , Canada.,d Department of Biochemistry , McGill University , Montréal , QC , Canada
| | - David Y Thomas
- b Cystic Fibrosis Translational Research centre , McGill University , Montréal , QC , Canada.,d Department of Biochemistry , McGill University , Montréal , QC , Canada.,e Department of Human Genetics , McGill University , Montréal , QC , Canada
| |
Collapse
|
13
|
Jansen G, Hefke T, Wittenberg G, Vordemvenne T, Mertzlufft F. [Positioning of external pelvic stabilization devices in patients with multiple injuries : Retrospective computed tomographic evaluation]. Anaesthesist 2018; 67:837-849. [PMID: 30298271 DOI: 10.1007/s00101-018-0494-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Revised: 08/28/2018] [Accepted: 09/03/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND Severe hemorrhage is a dreaded complication of pelvic fractures. It has a significant impact on early trauma-associated mortality. Hemorrhage that is secondary to pelvic fractures can be reduced by external stabilization devices. Despite the commercial availability of many different systems, they are infrequently used. The aim of this computed tomography (CT) study was to examine the use of external pelvic stabilization devices. METHODS Between 1 January 2011 and 31 December 2015 a total of 982 images produced in CT trauma scans at a level 1 trauma centre were retrospectively examined with respect to the presence of external pelvic stabilizers. The type of device applied, its actual position including deviation from optimal position as well as pelvic parameters and complications were determined. RESULTS In 67 out of 982 patients (6.82%) with suspected multiple trauma, an external pelvic stabilizer was employed. In 41.8% the devices were not placed in concordance with prevailing scientific knowledge, 53.73% of devices did not comply with the manufacturer's instructions and 51.85% of systems with pneumatic cuffs caused significant malrotation. In one patient the cuff induced hypoperfusion of the leg but without further sequelae. CONCLUSION While the prehospital use of pelvic slings is increasing, misplacement is very common. Especially inconsistencies between manufacturers' manuals and current scientific knowledge warrant further improvement. In systems with pneumatic cuffs malrotation of the device is common and clinically relevant. Hypoperfusion of the lower extremities is possible and should be taken into account when employing these devices.
Collapse
Affiliation(s)
- G Jansen
- Klinik für Anästhesiologie, Intensiv‑, Notfall‑, Transfusionsmedizin und Schmerztherapie, Evangelisches Klinikum Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland. .,Fachbereich Medizin und Rettungswesen, Studieninstitut für kommunale Verwaltung Westfalen-Lippe, Bielefeld, Deutschland.
| | - T Hefke
- Institut für diagnostische und interventionelle Radiologie und Kinderradiologie, Evangelisches Klinikum Bethel, Bielefeld, Deutschland
| | - G Wittenberg
- Institut für diagnostische und interventionelle Radiologie und Kinderradiologie, Evangelisches Klinikum Bethel, Bielefeld, Deutschland
| | - T Vordemvenne
- Klinik für Unfallchirurgie und Orthopädie, Evangelisches Klinikum Bethel, Bielefeld, Deutschland
| | - F Mertzlufft
- Evangelisches Klinikum Bethel, Burgsteig 13, 33617, Bielefeld, Deutschland
| |
Collapse
|
14
|
Banaz F, Edem I, Moldovan ID, Kilty S, Jansen G, Alkherayf F. Chondrosarcoma in the Petrous Apex: Case Report and Review. J Neurol Surg Rep 2018; 79:e83-e87. [PMID: 30473986 PMCID: PMC6193802 DOI: 10.1055/s-0038-1673627] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 08/28/2018] [Indexed: 11/12/2022] Open
Abstract
Introduction Surgical treatment of petrous apex chondrosarcoma is challenging due to the location of the tumor. Using an endoscopic technique for tumor resection is favored since it provides a minimally invasive approach. Case Presentation A 57 years old female was admitted for acute onset of left abducens nerve palsy and occasional headache mainly on the left side of the retro-orbital area with some radiation to the left occiput. Magnetic resonance imaging (MRI) and computed tomography (CT), at the time of admission, were showed lytic lesion on the left petrous apex and left part of the clivus. Results of metastatic workup were negative. The surgical procedure considered was expanded endoscopic endonasal transclival approach to the left of the petrous apex and reconstruction with a pedicled nasoseptal flap with image guidance system. The pathology confirmed chondrosarcoma on myxoid background. The surgical procedure was uncomplicated. The abducens nerve palsy was resolved in few weeks and no new deficits occurred. Postoperative MRI showed complete resection of the tumor. Conclusion Expanded endoscopic endonasal transclival approach to petrous apex and reconstruction appears to be safe and feasible technique, capable of achieving total removal of identified lesions near the petrous apex. Nonetheless, future studies with a greater number of patients are crucial to confirm and consolidate this initial impression.
Collapse
Affiliation(s)
- F. Banaz
- Department of Otolaryngology- Head & Neck Surgery, The Ottawa Hospital, Ottawa, Canada
| | - I. Edem
- Division of Neurosurgery, Department of Surgery, The Ottawa Hospital, Ottawa, Canada
- University of Ottawa, Faculty of Medicine, Ottawa, Canada
| | - I. D. Moldovan
- Division of Neurosurgery, Department of Surgery, The Ottawa Hospital, Ottawa, Canada
- The Ottawa Hospital Research Institute, Ottawa, Canada
| | - S. Kilty
- Department of Otolaryngology- Head & Neck Surgery, The Ottawa Hospital, Ottawa, Canada
- University of Ottawa, Faculty of Medicine, Ottawa, Canada
- The Ottawa Hospital Research Institute, Ottawa, Canada
| | - G. Jansen
- Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, Canada
- University of Ottawa, Faculty of Medicine, Ottawa, Canada
| | - F. Alkherayf
- Division of Neurosurgery, Department of Surgery, The Ottawa Hospital, Ottawa, Canada
- University of Ottawa, Faculty of Medicine, Ottawa, Canada
- The Ottawa Hospital Research Institute, Ottawa, Canada
| |
Collapse
|
15
|
Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struys EA, Perrino M, Jansen G, Matherly LH, Peters GJ. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol 2017; 28:2725-2732. [PMID: 28945836 PMCID: PMC5808668 DOI: 10.1093/annonc/mdx499] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma. PATIENTS AND METHODS PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue-microarrays, respectively, in two cohorts of pemetrexed-treated patients. Data were analyzed by t-test, Fisher's/log-rank test and Cox proportional models. The contribution of PCFT expression and PCFT-promoter methylation to pemetrexed activity were evaluated in mesothelioma cells and spheroids, through 5-aza-2'-deoxycytidine-mediated demethylation and siRNA-knockdown. RESULTS Pemetrexed-treated patients with low PCFT had significantly lower rates of disease control, and shorter overall survival (OS), in both the test (N = 73, 11.3 versus 20.1 months, P = 0.01) and validation (N = 51, 12.6 versus 30.3 months, P = 0.02) cohorts. Multivariate analysis confirmed PCFT-independent prognostic role. Low-PCFT protein levels were also associated with shorter OS. Patients with both low-PCFT and high-TS levels had the worst prognosis (OS, 5.5 months), whereas associations were neither found for RFC nor in pemetrexed-untreated patients. PCFT silencing reduced pemetrexed sensitivity, whereas 5-aza-2'-deoxycytidine overcame resistance. CONCLUSIONS These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression.
Collapse
Affiliation(s)
- E Giovannetti
- Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC Start-Up Unit, Department of Translational Research and The New Technologies in Medicine and Surgery, University of Pisa, Pisa
| | - P A Zucali
- Department of Oncology, University of Milan, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy
| | - Y G Assaraf
- Department of Biology, Fred Wyszkowski Cancer Research Laboratory, Technion-Institute of Technology, Haifa, Israel
| | - N Funel
- Cancer Pharmacology Lab, AIRC Start-Up Unit, Department of Translational Research and The New Technologies in Medicine and Surgery, University of Pisa, Pisa
| | - M Gemelli
- Department of Oncology, University of Milan, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy
| | - M Stark
- Department of Biology, Fred Wyszkowski Cancer Research Laboratory, Technion-Institute of Technology, Haifa, Israel
| | - E Thunnissen
- Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
| | - Z Hou
- Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
| | - I B Muller
- Department of Clinical Chemistry, VU University Medical Center, Amsterdam
| | - E A Struys
- Department of Clinical Chemistry, VU University Medical Center, Amsterdam
| | - M Perrino
- Department of Oncology, University of Milan, Humanitas Clinical and Research Hospital, Rozzano (Milan), Italy
| | - G Jansen
- Amsterdam Rheumatology and Immunology Center - Location VUmc, Amsterdam, The Netherlands
| | - L H Matherly
- Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
| | - G J Peters
- Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
| |
Collapse
|
16
|
Ganesamoorthy C, Heimann S, Hölscher S, Haack R, Wölper C, Jansen G, Schulz S. Synthesis, structure and dispersion interactions in bis(1,8-naphthalendiyl)distibine. Dalton Trans 2017; 46:9227-9234. [PMID: 28678236 DOI: 10.1039/c7dt02165h] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Naph2Sb21 was synthesized by a reaction of 1,8-dilithionaphthalene NaphLi2 with SbCl3 and its solid state structure is reported on. 1 shows intermolecular interactions in the solid state, which were studied by quantum chemical calculations with dispersion corrected density functional theory, supermolecular ab initio approaches and symmetry adapted perturbation theory. The same methods were employed to compare the solid state interactions in the crystal of 1 to those in real (for E = P) and hypothetical (for E = As and Bi) crystal structures of Naph2E2. Dispersion interactions were found to provide the most important stabilising contribution in all cases, seconded by electrostatic attraction between pnictogen atoms and π-systems of neighbouring naphthyl groups.
Collapse
Affiliation(s)
- C Ganesamoorthy
- University of Duisburg-Essen, Universitätsstr. 5-7, S07 S03 C30, 45117 Essen, Germany.
| | | | | | | | | | | | | |
Collapse
|
17
|
Jassby DL, Towner HH, Rütten HJ, Teuchert E, Mintz JM, Elleman TS, Verghese K, Lahr HWH, Lackey WJ, Stinton DP, Davis LE, Beatty RL, Burkholder HC, Cloninger MO, Baker DA, Jansen G, Katsuta H, Furukawa K, Bloom EE, Leitnaker JM, Stiegler JO, T. C. Gillet EE, Denning RS, Ridihalgh JL, Okawara GS, Harms AA, McKlveen JW, Schwenk M, Roger Billeter T, Blackburn LD, Davie RN, Davis JF, Schneider RT, Collier RK, Backus CE. Authors. NUCL TECHNOL 2017. [DOI: 10.13182/nt76-a31677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
18
|
Affiliation(s)
- H. C. Burkholder
- Battelle Pacific Northwest Laboratories, P.O. Box 999, Richland, Washington 99352
| | - M. O. Cloninger
- Battelle Pacific Northwest Laboratories, P.O. Box 999, Richland, Washington 99352
| | - D. A. Baker
- Battelle Pacific Northwest Laboratories, P.O. Box 999, Richland, Washington 99352
| | - G. Jansen
- Battelle Pacific Northwest Laboratories, P.O. Box 999, Richland, Washington 99352
| |
Collapse
|
19
|
Affiliation(s)
- G. Jansen
- Battelle Northwest Laboratories, Chemical Technology Department, P. O. Box 999, Richland, Washington 99352
| | - D. D. Stepnewski
- Westinghouse Hanford Company, Reactor and Safety Engineering Department P. O. Box 1970, Richland, Washington 99352
| |
Collapse
|
20
|
Jansen G, Schmidt B, Mertzlufft F, Boesing T, Barthel M. [CHAOS in neonatal emergency care? : Tracheal agenesis in the obstetric theatre]. Anaesthesist 2017; 65:763-767. [PMID: 27612864 DOI: 10.1007/s00101-016-0220-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Tracheal agenesis (TA) is a very rare congenital malformation of unknown aetiology. It is often associated with polymalformative syndromes; the neonates commonly present a critical condition during post-natal treatment. Pathology revolves around the triad of aphonia, respiratory distress syndrome and impossibility of endotracheal intubation. In contrast to the most important differential diagnosis, i. e., congenital high airway obstruction syndrome (CHAOS), surgical airway management is also impossible due to the absence of tracheal structures. In most cases, prognosis is very poor. The case report at hand portrays the treatment of a neonate suffering from tracheal agenesis.
Collapse
Affiliation(s)
- G Jansen
- Klinik für Anästhesiologie, Intensiv-, Notfall-, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld gGmbH, Burgsteig 13, 33617, Bielefeld, Deutschland.
| | - B Schmidt
- Klinik für Anästhesiologie, Intensiv-, Notfall-, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld gGmbH, Burgsteig 13, 33617, Bielefeld, Deutschland
| | - F Mertzlufft
- Klinik für Anästhesiologie, Intensiv-, Notfall-, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld gGmbH, Burgsteig 13, 33617, Bielefeld, Deutschland
| | - T Boesing
- Klinik für Kinder- und Jugendmedizin, Evangelisches Krankenhaus Bielefeld gGmbH, Bielefeld, Deutschland
| | - M Barthel
- Klinik für Kinderchirurgie, Evangelisches Krankenhaus Bielefeld gGmbH, Bielefeld, Deutschland
| |
Collapse
|
21
|
Jansen G, Leimkühler K, Mertzlufft F. Intramedulläre Lage von präklinisch angelegten intraossären Zugängen bei polytraumatisierten Patienten. Anaesthesist 2017; 66:168-176. [DOI: 10.1007/s00101-016-0257-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 11/28/2016] [Accepted: 11/30/2016] [Indexed: 11/28/2022]
|
22
|
Szili-Torok T, Nölker G, Spitzer S, Sommer P, Brachmann J, Deneke T, Keweloh B, Jansen G, Luik A, Schmitt C, Hindricks G. 209-02: European-Focal Impulse and Rotor Modulation Registry –First Results of the E-FIRM Registry. Europace 2016. [DOI: 10.1093/europace/18.suppl_1.i140a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Jansen G, Mertzlufft F, Bach F. Präklinische Routine? Ein besonderer Fall von akutem Koronarsyndrom. Notf Rett Med 2016. [DOI: 10.1007/s10049-016-0132-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Jansen G, Mertzlufft F. [Isadora Duncan syndrome : Lethal strangulation injuries caused by filling equipment]. Anaesthesist 2016; 65:359-62. [PMID: 27142365 DOI: 10.1007/s00101-016-0165-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 03/03/2016] [Accepted: 03/11/2016] [Indexed: 10/21/2022]
Abstract
Aside from suicide attempts or autoerotic accidents, serious injuries from strangulation are rare. In 1929, the accidental death of the famous dancer Isadora Duncan gained high profile. However, even today there are reports of accidental strangulations. These are referred to as Isadora Duncan or long-scarf syndrome and are oftentimes lethal. In the pre-hospital setting, airway management has been challenging, as even a correctly placed airway device may initiate a rapid and marked deterioration of the patient's condition. The case history at hand outlines the death of a 47-year-old female, following entanglement of her scarf in bottling equipment.
Collapse
Affiliation(s)
- G Jansen
- Klinik für Anästhesiologie, Intensiv-, Notfall-, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland. .,Fachbereich Medizin und Rettungswesen, Studieninstitut für kommunale Verwaltung Westfalen-Lippe, Westfalen-Lippe, Deutschland.
| | - F Mertzlufft
- Klinik für Anästhesiologie, Intensiv-, Notfall-, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland
| |
Collapse
|
25
|
Waller DD, Jansen G, Golizeh M, Martel-Lorion C, Dejgaard K, Shiao TC, Mancuso J, Tsantrizos YS, Roy R, Sebag M, Sleno L, Thomas DY. A Covalent Cysteine-Targeting Kinase Inhibitor of Ire1 Permits Allosteric Control of Endoribonuclease Activity. Chembiochem 2016; 17:843-51. [PMID: 26792008 DOI: 10.1002/cbic.201500485] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Indexed: 11/12/2022]
Abstract
The unfolded protein response (UPR) initiated by the transmembrane kinase/ribonuclease Ire1 has been implicated in a variety of diseases. Ire1, with its unique position in the UPR, is an ideal target for the development of therapies; however, the identification of specific kinase inhibitors is challenging. Recently, the development of covalent inhibitors has gained great momentum because of the irreversible deactivation of the target. We identified and determined the mechanism of action of the Ire1-inhibitory compound UPRM8. MS analysis revealed that UPRM8 inhibition occurs by covalent adduct formation at a conserved cysteine at the regulatory DFG+2 position in the Ire1 kinase activation loop. Mutational analysis of the target cysteine residue identified both UPRM8-resistant and catalytically inactive Ire1 mutants. We describe a novel covalent inhibition mechanism of UPRM8, which can serve as a lead for the rational design and optimization of inhibitors of human Ire1.
Collapse
Affiliation(s)
- Daniel D Waller
- Department of Medicine, McGill University, 1001 Boulevard Décarie, Montréal, QC, H4A 3J1, Canada. .,Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Montréal, QC, H3G 1Y6, Canada.
| | - Gregor Jansen
- Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Montréal, QC, H3G 1Y6, Canada
| | - Makan Golizeh
- Pharmaqam, Département de Chimie, Université du Québec à Montréal, Montréal, QC, H3C 3P8, Canada
| | - Chloe Martel-Lorion
- Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Montréal, QC, H3G 1Y6, Canada
| | - Kurt Dejgaard
- Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Montréal, QC, H3G 1Y6, Canada
| | - Tze Chieh Shiao
- Pharmaqam, Département de Chimie, Université du Québec à Montréal, Montréal, QC, H3C 3P8, Canada
| | - John Mancuso
- Department of Chemistry, McGill University, 801 Sherbrooke St. West, Montréal, QC, H3G 1Y6, Canada
| | - Youla S Tsantrizos
- Department of Chemistry, McGill University, 801 Sherbrooke St. West, Montréal, QC, H3G 1Y6, Canada
| | - René Roy
- Pharmaqam, Département de Chimie, Université du Québec à Montréal, Montréal, QC, H3C 3P8, Canada
| | - Michael Sebag
- Department of Medicine, McGill University, 1001 Boulevard Décarie, Montréal, QC, H4A 3J1, Canada
| | - Lekha Sleno
- Pharmaqam, Département de Chimie, Université du Québec à Montréal, Montréal, QC, H3C 3P8, Canada
| | - David Y Thomas
- Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Montréal, QC, H3G 1Y6, Canada
| |
Collapse
|
26
|
Abstract
Many biological processes are regulated by protein-protein interactions, and the analysis of these interactions has been a productive endeavor contributing to our understanding of cellular organization and function. The yeast two-hybrid technique is a widely used, powerful method of analyzing protein-protein interactions. The currently used formats, however, have inherent limitations, providing an opportunity to develop new alternatives that extend our ability to detect protein-protein interactions of biological relevance. Here we present a two-hybrid system named SRYTH (Ste11p/Ste50p related yeast two-hybrid) based on the Ste11p/Ste50p interaction that uses the activation of the HOG pathway of Saccharomyces cerevisiae as a reporter for interactions. The system is suitable for detecting cytoplasmic protein interactions in their natural subcellular environment, and has been successfully used to investigate protein-protein interactions, including transcription factor associations, in Candida albicans.
Collapse
Affiliation(s)
- Jaideep Mallick
- Biology Department, Concordia University, 7141 Sherbrooke St. West, Montreal, QC, Canada, H4B 1R6
| | - Gregor Jansen
- Biochemistry Department, McGill University, 3655 Promenade Sir William Osler, Montreal, QC, Canada, H3G 1Y6
| | - Cunle Wu
- National Research Council of Canada, 6100 Royalmount Ave, Montreal, QC, Canada, H4P 2R2.,Division of Experimental Medicine, McGill University, 1100 Pine Ave.West, Montreal, QC, Canada, H3A 1A3
| | - Malcolm Whiteway
- Biology Department, Concordia University, 7141 Sherbrooke St. West, Montreal, QC, Canada, H4B 1R6.
| |
Collapse
|
27
|
Jansen G, Mertzlufft F, Bach F. [Reversible cerebral vasoconstriction syndrome. Challenge for diagnostics and intensive care therapy]. Anaesthesist 2015; 64:574-9. [PMID: 26194650 DOI: 10.1007/s00101-015-0053-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Revised: 05/03/2015] [Accepted: 05/21/2015] [Indexed: 10/23/2022]
Abstract
Reversible cerebral vasoconstriction syndrome (RCVS) is a disease of unclear incidence frequently affecting middle aged women and is usually associated with use of adrenergic or serotoninergic substances. The exclusion of relevant differential diagnoses, such as aneurysmal subarachnoid hemorrhage, primary cerebral angiitis, posterior reversible encephalopathy syndrome and carotid artery dissection is critical in terms of time and significance. Thunderclap headache as well as multiple and multilocular vasospasms with direct or indirect angiography without substantial findings in cerebrospinal fluid diagnostics are typical symptoms. The necessity for intensive care treatment is often justified by initial acute impairment of vital functions and possible development of cerebral or extracerebral complications. Because the exact pathophysiology remains unknown, a specific therapy does not exist. This poses significant challenges in intensive care medicine, which are illustrated on the basis of the case study presented.
Collapse
Affiliation(s)
- G Jansen
- Klinik für Anästhesiologie, Intensiv-, Notfall- Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland,
| | | | | |
Collapse
|
28
|
van der Laken C, Chandrupatla D, Molthoff C, Jansen G, Greeuw I, Verlaan M, van Kooij R, Bloemendaal M, Windhorst B, Lammertsma A, Low P, Qingshou C. AB0116 In Vivo Evaluation of Folate Receptor Expression in Relation to Methotrexate Treatment Efficacy in Arthritic Rats Using [18F]-PEG-Folate PET. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Kanungo R, Sanetullaev A, Tanaka J, Ishimoto S, Hagen G, Myo T, Suzuki T, Andreoiu C, Bender P, Chen AA, Davids B, Fallis J, Fortin JP, Galinski N, Gallant AT, Garrett PE, Hackman G, Hadinia B, Jansen G, Keefe M, Krücken R, Lighthall J, McNeice E, Miller D, Otsuka T, Purcell J, Randhawa JS, Roger T, Rojas A, Savajols H, Shotter A, Tanihata I, Thompson IJ, Unsworth C, Voss P, Wang Z. Evidence of soft dipole resonance in ^{11}li with isoscalar character. Phys Rev Lett 2015; 114:192502. [PMID: 26024166 DOI: 10.1103/physrevlett.114.192502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Indexed: 06/04/2023]
Abstract
The first conclusive evidence of a dipole resonance in ^{11}Li having isoscalar character observed from inelastic scattering with a novel solid deuteron target is reported. The experiment was performed at the newly commissioned IRIS facility at TRIUMF. The results show a resonance peak at an excitation energy of 1.03±0.03 MeV with a width of 0.51±0.11 MeV (FWHM). The angular distribution is consistent with a dipole excitation in the distorted-wave Born approximation framework. The observed resonance energy together with shell model calculations show the first signature that the monopole tensor interaction is important in ^{11}Li. The first ab initio calculations in the coupled cluster framework are also presented.
Collapse
Affiliation(s)
- R Kanungo
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - A Sanetullaev
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - J Tanaka
- RCNP, Osaka University, Mihogaoka, Ibaraki, Osaka 567 0047, Japan
| | - S Ishimoto
- High Energy Accelerator Research Organization (KEK), Ibaraki 305-0801, Japan
| | - G Hagen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - T Myo
- General Education, Faculty of Engineering, Osaka Institute of Technology, Osaka, Osaka 535-8585, Japan
| | - T Suzuki
- Department of Physics, Nihon University, Setagaya-ku, Tokyo 156-8550, Japan
| | - C Andreoiu
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| | - P Bender
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - A A Chen
- Department of Physics and Astronomy, McMaster University, Hamilton, Ontario L8S 4M1, Canada
| | - B Davids
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - J Fallis
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - J P Fortin
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
- Department of Physics, University of Laval, Quebec City, Quebec G1V 0A8, Canada
| | - N Galinski
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - A T Gallant
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - P E Garrett
- Department of Physics, University of Guelph, Guelph, Ontario N1G 2W1, Canada
| | - G Hackman
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - B Hadinia
- Department of Physics, University of Guelph, Guelph, Ontario N1G 2W1, Canada
| | - G Jansen
- Physics Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - M Keefe
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - R Krücken
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
- Department of Physics and Astronomy, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | - J Lighthall
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - E McNeice
- Department of Physics and Astronomy, McMaster University, Hamilton, Ontario L8S 4M1, Canada
| | - D Miller
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - T Otsuka
- Department of Physics and Center of Nuclear Studies, University of Tokyo, Bunky-ku, Tokyo 113-0033, Japan
| | - J Purcell
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - J S Randhawa
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - T Roger
- Grand Accélérateur National dIons Lourds, CEA/DSM-CNRS/IN2P3, B.P. 55027, F-14076 Caen Cedex 5, France
| | - A Rojas
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - H Savajols
- Grand Accélérateur National dIons Lourds, CEA/DSM-CNRS/IN2P3, B.P. 55027, F-14076 Caen Cedex 5, France
| | - A Shotter
- School of Physics and Astronomy, University of Edinburgh, EH9 3JZ, Edinburgh, United Kingdom
| | - I Tanihata
- RCNP, Osaka University, Mihogaoka, Ibaraki, Osaka 567 0047, Japan
- School of Physics and Nuclear Energy Engineering and IRCNPC, Beihang University, Beijing 100191, China
| | - I J Thompson
- Lawrence Livermore National Laboratory, L-414, Livermore, California 94551, USA
| | - C Unsworth
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
| | - P Voss
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| | - Z Wang
- TRIUMF, Vancouver, British Columbia V6T2A3, Canada
- Department of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| |
Collapse
|
30
|
de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, Jansen G, Mantel E, Lübbers J, de Ridder S, Voskuyl AE, Verweij CL. A7.14 Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
31
|
Tsang-A-Sjoe MWP, de Groot KA, Niewerth D, Cloos J, Blank JL, Zweegman S, Jansen G, Voskuyl AE, van der Heijden JW. A8.17 Effective use of bortezomib and plasma filtration in a critically ill patient with lupus nephritis and myocarditis: a case report and dynamics of (immuno) proteasome inhibition. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-207259.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Naglav D, Neumann A, Bläser D, Wölper C, Haack R, Jansen G, Schulz S. Bonding situation in Be[N(SiMe3)2]2 – an experimental and computational study. Chem Commun (Camb) 2015; 51:3889-91. [DOI: 10.1039/c4cc09732g] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The solid state structure of Be[N(SiMe3)2]2 (1) was determined by in situ crystallisation and the bonding situation investigated by quantum chemical calculations. The Be–N bond is predominantly ionic but also shows some π-bonding character.
Collapse
Affiliation(s)
- D. Naglav
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - A. Neumann
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - D. Bläser
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - C. Wölper
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - R. Haack
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - G. Jansen
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - S. Schulz
- University of Duisburg-Essen
- 45117 Essen
- Germany
| |
Collapse
|
33
|
Abstract
MeL2Zn2(μ-1,6-Ph2-N6) 1 (MeL = HC[C(Me)N(2,4,6-Me3C6H2)]2) serves as hexazene transfer reagent in reactions with main group metal and transition metal complexes containing M–Me units.
Collapse
Affiliation(s)
- S. Gondzik
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - C. Wölper
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - R. Haack
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - G. Jansen
- University of Duisburg-Essen
- 45117 Essen
- Germany
| | - S. Schulz
- University of Duisburg-Essen
- 45117 Essen
- Germany
| |
Collapse
|
34
|
Batink T, Jansen G, Peeters FPML. [New generation behaviour therapy; new generation assessment measures; a review of currently available assessment measures]. Tijdschr Psychiatr 2015; 57:739-748. [PMID: 26479254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND Acceptance and commitment therapy (ACT) is a relatively new form of behaviour therapy, which has relational frame theory as its theoretical foundation. Since ACT is not aimed primarily at reducing psychopathological symptoms, changes are likely to be needed in the nature and purpose of the assessment measures used. AIM To provide an up-to-date overview of ACT-measures that are suitable for use with adults and that will assist Dutch-speaking clinicians and researchers. METHOD We performed a systematic review of the literature. RESULTS More than 50 ACT-related questionnaires were identified; of these, the AAQ-II was the most suitable for acceptance as an act component, the CFQ was the most appropriate for defusion and the SACS was the best for self as context; the FFMQ-SF was regarded as the best for contact with the present moment, the VLQ for values, the ELS for committed action and the FIT-60 for psychological flexibility. CONCLUSION Clinicians and researchers with an interest in ACT have many measures at their disposal. Most of these are available free of charge and can also be used without payment.
Collapse
|
35
|
Milanesi M, Vicario D, Stella A, Valentini A, Ajmone-Marsan P, Biffani S, Biscarini F, Jansen G, Nicolazzi EL. Imputation accuracy is robust to cattle reference genome updates. Anim Genet 2014; 46:69-72. [PMID: 25515631 DOI: 10.1111/age.12251] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2014] [Indexed: 11/26/2022]
Abstract
Genotype imputation is routinely applied in a large number of cattle breeds. Imputation has become a need due to the large number of SNP arrays with variable density (currently, from 2900 to 777,962 SNPs). Although many authors have studied the effect of different statistical methods on imputation accuracy, the impact of a (likely) change in the reference genome assembly on imputation from lower to higher density has not been determined so far. In this work, 1021 Italian Simmental SNP genotypes were remapped on the three most recent reference genome assemblies. Four imputation methods were used to assess the impact of an update in the reference genome. As expected, the four methods behaved differently, with large differences in terms of accuracy. Updating SNP coordinates on the three tested cattle reference genome assemblies determined only a slight variation on imputation results within method.
Collapse
Affiliation(s)
- M Milanesi
- Istituto di Zootecnica, Università Cattolica del Sacro Cuore, via Emilia Parmense 84, Piacenza, 29122, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Linder J, Jansen G, Ekholm K, Ekholm J. Relationship between sleep disturbance, pain, depression and functioning in long-term sick-listed patients experiencing difficulty in resuming work. J Rehabil Med 2014; 46:798-805. [DOI: 10.2340/16501977-1833] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
37
|
Gondzik S, Schulz S, Bläser D, Wölper C, Haack R, Jansen G. Reactions of a Zn(i) complex with group 14 azides – formation of zinc azide and zinc hexazene complexes. Chem Commun (Camb) 2014; 50:927-9. [DOI: 10.1039/c3cc47687a] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
38
|
Jansen G, Popp J, Dietrich U, Mertzlufft F, Bach F. [Traumatic dissection of the carotid artery: challenges for diagnostics and therapy illustrated by a case example]. Anaesthesist 2013; 62:817-23. [PMID: 24057761 DOI: 10.1007/s00101-013-2243-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 08/28/2013] [Accepted: 08/28/2013] [Indexed: 11/24/2022]
Abstract
Traumatic dissection of the carotid artery is an easily overlooked consequence of trauma with notable morbidity and mortality which can be observed in up to 4% of cases involving multiple trauma. Certain mechanisms and patterns of injury as well as specific symptoms should serve as indicators of a dissection and should therefore result in further diagnostic measures. An early diagnosis is of major relevance. This report describes the case of a 45-year-old victim of a traffic accident who showed symptoms of a dissection which had initially not been diagnosed.
Collapse
Affiliation(s)
- G Jansen
- Klinik für Anästhesie, Intensiv-, Notfall-, Transfusionsmedizin und Schmerztherapie, Evangelisches Krankenhaus, Burgsteig 13, 33617, Bielefeld, Deutschland,
| | | | | | | | | |
Collapse
|
39
|
Lans H, Lindvall JM, Thijssen K, Karambelas AE, Cupac D, Fensgård O, Jansen G, Hoeijmakers JHJ, Nilsen H, Vermeulen W. DNA damage leads to progressive replicative decline but extends the life span of long-lived mutant animals. Cell Death Differ 2013; 20:1709-18. [PMID: 24013725 PMCID: PMC3824592 DOI: 10.1038/cdd.2013.126] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Revised: 07/18/2013] [Accepted: 08/01/2013] [Indexed: 11/09/2022] Open
Abstract
Human-nucleotide-excision repair (NER) deficiency leads to different developmental and segmental progeroid symptoms of which the pathogenesis is only partially understood. To understand the biological impact of accumulating spontaneous DNA damage, we studied the phenotypic consequences of DNA-repair deficiency in Caenorhabditis elegans. We find that DNA damage accumulation does not decrease the adult life span of post-mitotic tissue. Surprisingly, loss of functional ERCC-1/XPF even further extends the life span of long-lived daf-2 mutants, likely through an adaptive activation of stress signaling. Contrariwise, NER deficiency leads to a striking transgenerational decline in replicative capacity and viability of proliferating cells. DNA damage accumulation induces severe, stochastic impairment of development and growth, which is most pronounced in NER mutants that are also impaired in their response to ionizing radiation and inter-strand crosslinks. These results suggest that multiple DNA-repair pathways can protect against replicative decline and indicate that there might be a direct link between the severity of symptoms and the level of DNA-repair deficiency in patients.
Collapse
Affiliation(s)
- H Lans
- Department of Genetics, Biomedical Science, Erasmus MC, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
van der Heijden JW, Assaraf YG, Gerards AH, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BAC, Jansen G. Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients. Scand J Rheumatol 2013; 43:9-16. [PMID: 23987246 DOI: 10.3109/03009742.2013.797490] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVES Although methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA), patients experience clinical resistance to MTX upon prolonged treatment. We explored whether new-generation antifolates elicit superior anti-inflammatory properties when compared to MTX, based on their capacity to inhibit tumour necrosis factor (TNF)-α production. METHOD T cells in whole blood from 18 RA patients (including MTX-naïve, MTX- responsive, and MTX non-responsive patients) and seven healthy volunteers were stimulated with αCD3/αCD28 antibodies and incubated ex vivo for 72 h with MTX and eight novel antifolate drugs with potentially favourable biochemical and pharmacological properties. Drug concentrations exerting 50% inhibition (IC-50) of TNF-α production (by enzyme-linked immunosorbent assay, ELISA) were determined as an estimate for their anti-inflammatory capacity. In addition, induction of T-cell apoptosis was evaluated by flow cytometry. RESULTS The new-generation antifolates PT523, PT644, raltitrexed, and GW1843 proved to be potent inhibitors of TNF-α production in activated T cells from all three groups of RA patients and from healthy volunteers. Based on IC-50 values, these antifolates were up to 10.3 times more potent than MTX. The anti-inflammatory effects were observed at drug concentrations that provoked suppression of T-cell activation and induction of apoptosis in 20-40% of activated T cells. CONCLUSION In an ex-vivo setting, novel antifolates elicited marked inhibition of TNF-α production in activated T cells from RA patients. Further clinical evaluation is warranted to investigate whether a low dosage of these antifolates can elicit immunosuppressive effects equivalent to MTX, and whether they are superior to MTX in patients who fail to respond to MTX.
Collapse
Affiliation(s)
- J W van der Heijden
- Department of Rheumatology, VU University Medical Center , Amsterdam , The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Roest W, Rooijen MV, Kwa D, Jansen G, Vries HD. O18.5 False Negative HSV IgG1 and IgG2 Antibody Responses in Individuals with a Recurrent Genital Herpes Infection. Sex Transm Infect 2013. [DOI: 10.1136/sextrans-2013-051184.0189] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
42
|
Gent YY, Weijers K, Molthoff CF, Windhorst AD, Huisman MC, Smith DE, Kularatne SA, Jansen G, Low PS, Lammertsma AA, van der Laken CJ. AB0761 Synthesis and evaluation of the novel folate receptor ligand [18f]fluoro-peg-folate for macrophage targeting in a rat model of arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.3083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Gent Y, Weijers K, Molthoff C, Windhorst A, de Greeuw I, Al M, Bergstra R, Verlaan M, Kassiou M, Lammertsma A, Jansen G, van der Laken C. OP0235 Pet high affinity translocator protein ligands as a novel modality for macrophage targeting in arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
Nicolazzi EL, Biffani S, Jansen G. Short communication: imputing genotypes using PedImpute fast algorithm combining pedigree and population information. J Dairy Sci 2013; 96:2649-2653. [PMID: 23462161 DOI: 10.3168/jds.2012-6062] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2012] [Accepted: 01/02/2013] [Indexed: 11/19/2022]
Abstract
Routine genomic evaluations frequently include a preliminary imputation step, requiring high accuracy and reduced computing time. A new algorithm, PedImpute (http://dekoppel.eu/pedimpute/), was developed and compared with findhap (http://aipl.arsusda.gov/software/findhap/) and BEAGLE (http://faculty.washington.edu/browning/beagle/beagle.html), using 19,904 Holstein genotypes from a 4-country international collaboration (United States, Canada, UK, and Italy). Different scenarios were evaluated on a sample subset that included only single nucleotide polymorphism from the Bovine low-density (LD) Illumina BeadChip (Illumina Inc., San Diego, CA). Comparative criteria were computing time, percentage of missing alleles, percentage of wrongly imputed alleles, and the allelic squared correlation. Imputation accuracy on ungenotyped animals was also analyzed. The algorithm PedImpute was slightly more accurate and faster than findhap and BEAGLE when sire, dam, and maternal grandsire were genotyped at high density. On the other hand, BEAGLE performed better than both PedImpute and findhap for animals with at least one close relative not genotyped or genotyped at low density. However, computing time and resources using BEAGLE were incompatible with routine genomic evaluations in Italy. Error rate and allelic squared correlation attained by PedImpute ranged from 0.2 to 1.1% and from 96.6 to 99.3%, respectively. When complete genomic information on sire, dam, and maternal grandsire are available, as expected to be the case in the close future in (at least) dairy cattle, and considering accuracies obtained and computation time required, PedImpute represents a valuable choice in routine evaluations among the algorithms tested.
Collapse
Affiliation(s)
- E L Nicolazzi
- Consorzio di Ricerca e Sperimentazione degli Allevatori (CRSA), Via G. Tomassetti 9, Rome 00161, Italy; Parco Tecnologico Padano, Via Einstein, Lodi (LO) 26900, Italy.
| | - S Biffani
- Associazione Nazionale Allevatori Frisona Italiana (ANAFI), Via Bergamo 292, Cremona (CR) 26100, Italy
| | - G Jansen
- Associazione Nazionale Allevatori Frisona Italiana (ANAFI), Via Bergamo 292, Cremona (CR) 26100, Italy; Dekoppel Consulting, Casale Rovera 10, Chiaverano (TO) 10010, Italy
| |
Collapse
|
45
|
Rademakers S, Broekhuis J, Dekkers M, Burghoorn J, Jansen G. The GMAP210 homologue SQL 1 modulates intraflagellar transport in C. elegans. Cilia 2012. [PMCID: PMC3555974 DOI: 10.1186/2046-2530-1-s1-p40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
46
|
Jansen G, Broekhuis JR. Regulation of cilium length and intraflagellar transport by the MAP kinases MAK, MRK, and MOK. Cilia 2012. [PMCID: PMC3555793 DOI: 10.1186/2046-2530-1-s1-o12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
|
47
|
Beets I, Janssen T, Meelkop E, Temmerman L, Suetens N, Rademakers S, Jansen G, Schoofs L. Vasopressin/Oxytocin-Related Signaling Regulates Gustatory Associative Learning in C. elegans. Science 2012; 338:543-5. [DOI: 10.1126/science.1226860] [Citation(s) in RCA: 134] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
48
|
|
49
|
de Wilt LHAM, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FAE. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol 2012; 85:363-72. [PMID: 22944363 DOI: 10.1016/j.critrevonc.2012.08.001] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2012] [Revised: 07/13/2012] [Accepted: 08/06/2012] [Indexed: 01/11/2023] Open
Abstract
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine that selectively eradicates tumour cells via specific cell surface receptors and is intensively explored for use as a novel anticancer approach. To enhance the efficacy of TRAIL receptor agonists the proteasome inhibitor bortezomib is one of the most potent sensitizers. Here we review the main mechanisms underlying bortezomib-dependent TRAIL sensitization, including stimulation of apoptosis by increasing expression of TRAIL receptors, reduction of cFLIP and enhancement of caspase 8 activation, and modulation of Bcl-2 family proteins and inhibitor of apoptosis proteins (IAPs). Concomitantly, pro-survival signals are suppressed such as elicited by NF-κB and Akt. The different preclinical tumour models explored with this combination, including primary tumour (stem) cells, stroma co-culture and mice models, are discussed, as well as possible hurdles for clinical activity. Collectively, anticipating a solid rationale for bortezomib-TRAIL combination and very promising preclinical results, its clinical activity remains to be demonstrated.
Collapse
Affiliation(s)
- L H A M de Wilt
- Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
50
|
Jansen G, Määttänen P, Denisov AY, Scarffe L, Schade B, Balghi H, Dejgaard K, Chen LY, Muller WJ, Gehring K, Thomas DY. An interaction map of endoplasmic reticulum chaperones and foldases. Mol Cell Proteomics 2012; 11:710-23. [PMID: 22665516 DOI: 10.1074/mcp.m111.016550] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Chaperones and foldases in the endoplasmic reticulum (ER) ensure correct protein folding. Extensive protein-protein interaction maps have defined the organization and function of many cellular complexes, but ER complexes are under-represented. Consequently, chaperone and foldase networks in the ER are largely uncharacterized. Using complementary ER-specific methods, we have mapped interactions between ER-lumenal chaperones and foldases and describe their organization in multiprotein complexes. We identify new functional chaperone modules, including interactions between protein-disulfide isomerases and peptidyl-prolyl cis-trans-isomerases. We have examined in detail a novel ERp72-cyclophilin B complex that enhances the rate of folding of immunoglobulin G. Deletion analysis and NMR reveal a conserved surface of cyclophilin B that interacts with polyacidic stretches of ERp72 and GRp94. Mutagenesis within this highly charged surface region abrogates interactions with its chaperone partners and reveals a new mechanism of ER protein-protein interaction. This ability of cyclophilin B to interact with different partners using the same molecular surface suggests that ER-chaperone/foldase partnerships may switch depending on the needs of different substrates, illustrating the flexibility of multichaperone complexes of the ER folding machinery.
Collapse
Affiliation(s)
- Gregor Jansen
- Department of Biochemistry, McGill University, Montréal, Québec H3G 1Y6, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|